Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | RBP4 | P02753 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | HTR1F | P30939 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | UBE2M | P61081 | 1/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544187 | 0.86 | PTGDR2 (0.42) | HPGDPTGDR2IDO1TBXA2R | |
| SCHEMBL3543676 | 0.86 | MAPK14 (0.40) | HPGDPTGDR2TBXA2RMGLL | |
| SCHEMBL5743280 | 0.84 | SLC6A9 (0.42) | GRM5SCD5HSD11B1PTGDR2MGLL | |
| SCHEMBL3546483 | 0.83 | LMNA (0.36) | OPRL1PTGDR2 | |
| SCHEMBL3538233 | 0.81 | DRD4 (0.35) | OPRL1PTGDR2 | |
| SCHEMBL3541664 | 0.80 | SLC6A9 (0.41) | HSD11B1 | |
| SCHEMBL5742641 | 0.79 | RBP4 (0.36) | GRM5SCD5OPRL1RBP4PTGDR2 | |
| SCHEMBL3546985 | 0.78 | SLC6A9 (0.42) | HSD11B1MGLL | |
| SCHEMBL3547182 | 0.77 | TBXA2R (0.40) | GRM5PTGDR2IDO1TBXA2RMGLL | |
| Oxalic Acid SCHEMBL3548493 | 0.76 | SLC6A2 (0.43) | LDHAOPRL1HPGDTBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732463-B2 | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2010-06-08 | — | — | US | disclosed |
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | H.LUNDBECK A/S (DK) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | HTR4, HTR5A, TPH1 | GRM5 45/4885LDHA 1165/4885SCD5 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.